BL
MCID: BRK010
MIFTS: 68

Burkitt Lymphoma (BL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Burkitt Lymphoma

MalaCards integrated aliases for Burkitt Lymphoma:

Name: Burkitt Lymphoma 57 12 53 59 75 37 29 13 55 6 44 15 38 40 73
Burkitt's Lymphoma 38 12 76 53 15
Bl 57 53 75
Small Non-Cleaved Cell Lymphoma, Burkitt's Type 12
Malignant Lymphoma, Burkitt's Type 12
Small Non-Cleaved Cell Lymphoma 59
Lymphoma, Small Noncleaved-Cell 73
Burkitt's Tumor or Lymphoma 12
Burkitt Lymphoma/leukaemia 12
Burkitt's Tumor 12
Burkitt Tumor 75

Characteristics:

Orphanet epidemiological data:

59
burkitt lymphoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-5/10000 (Africa),1-9/1000000 (United States); Age of onset: All ages; Age of death: any age;

OMIM:

57
Inheritance:
isolated cases

Miscellaneous:
accounts for 30-50% of lymphomas in children
accounts for 1-2% of lymphomas in adults
three distinct clinical forms - endemic (equatorial africa), sporadic, and immunodeficiency-associated (e.g., hiv infection)


HPO:

32
burkitt lymphoma:
Inheritance sporadic


Classifications:



External Ids:

OMIM 57 113970
Disease Ontology 12 DOID:8584
ICD10 33 C83.7 C83.70
ICD9CM 35 200.2
MeSH 44 D002051
NCIt 50 C2912 C7400
SNOMED-CT 68 22197008 77381001
Orphanet 59 ORPHA543
UMLS via Orphanet 74 C0006413 C0079770
ICD10 via Orphanet 34 C83.7
MESH via Orphanet 45 D002051 D008228
MedGen 42 C0006413
KEGG 37 H00008

Summaries for Burkitt Lymphoma

NIH Rare Diseases : 53 Burkitt lymphoma (BL) is a very fast-growing type of cancer. It is a form of B-cellnon-Hodgkin's lymphoma. There are 3 recognized forms of BL: Endemic (African) - the most common form, found mainly in central Africa, where it is associated with the Epstein Barr virus (EBV). It is most common in children. This form often manifests as enlargement of the jaw or facial bones. Sporadic - a rarer form, seen in all parts of the world, that often develops in the abdomen with bone marrow involvement. The kidneys, ovaries, breasts or other organs may also be involved. This form commonly affects children and young adults. Immunodeficiency-associated - occurs primarily in people with HIV infection, and less commonly in people with other immunodeficiency disorders or recipients of organ transplants. Signs and symptoms may differ depending on the form of BL and the organs or body systems involved. When it spreads, weakness and fatigue often develop. Lymphoma cells may build up in the lymph nodes and other organs, causing swelling. Central nervous system involvement is possible with all forms of BL, particularly when there is advanced-stage disease.The exact cause of BL is not known. EBV infection appears to play a role in virtually all cases of endemic (African) BL, and a minority of sporadic and immunodeficiency-associated BL. While acquired (not inherited) genetic changes involving the MYC gene and other genes are present within BL cancer cells, it is unclear what causes these genetic changes to occur. Without timely treatment, BL is rapidly fatal. Treatment involves intensive chemotherapy, which includes chemotherapy to the fluid surrounding the brain and spinal cord. The majority of people treated with aggressive therapy achieve long-term remission.

MalaCards based summary : Burkitt Lymphoma, also known as burkitt's lymphoma, is related to lymphoma and diffuse large b-cell lymphoma. An important gene associated with Burkitt Lymphoma is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Viral carcinogenesis and Epstein-Barr virus infection. The drugs Abraxane and Abstral have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are nausea and vomiting and hyperuricemia

Disease Ontology : 12 A mature B-cell neoplasm of B-cells found in the germinal center.

OMIM : 57 Burkitt lymphoma is a rare, aggressive B-cell lymphoma that accounts for 30 to 50% of lymphomas in children but only 1 to 2% of lymphomas in adults (Harris and Horning, 2006). It results from chromosomal translocations that involve the MYC gene (190080) and either the lambda or the kappa light chain immunoglobulin genes (147220, 147200). Burkitt lymphoma is causally related to the Epstein-Barr virus (EBV), although the pathogenetic mechanisms are not clear. (113970)

UniProtKB/Swiss-Prot : 75 Burkitt lymphoma: A form of undifferentiated malignant lymphoma commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass.

Wikipedia : 76 Burkitt lymphoma is a cancer of the lymphatic system, particularly B lymphocytes found in the germinal... more...

Related Diseases for Burkitt Lymphoma

Diseases related to Burkitt Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 211)
# Related Disease Score Top Affiliating Genes
1 lymphoma 32.3 BAX BCL6 BCL7A CXCR5 MYC PVT1
2 diffuse large b-cell lymphoma 31.1 BCL6 MIR127 MIR143 MIR145 MIR155 MYC
3 b-cell lymphomas 31.0 AICDA BAX BCL6 MS4A1 MYC PVT1
4 lymphoma, hodgkin, classic 30.6 BCL6 MIR155 PVT1
5 follicular lymphoma 30.5 AICDA BCL6 MIR155 MS4A1 MYC
6 acquired immunodeficiency syndrome 30.3 BCL6 MYC NEAT1
7 lymphoma, non-hodgkin, familial 30.3 AICDA BAX BCL6 CXCR5 MS4A1 MYC
8 plasmablastic lymphoma 30.1 BCL6 MS4A1 MYC
9 leukemia, chronic lymphocytic 30.1 AICDA BAX BCL6 CXCR5 MS4A1
10 suppressor of tumorigenicity 3 30.1 BAX MYC
11 composite lymphoma 30.1 BCL6 SOX11
12 leukemia, acute myeloid 29.5 MIR155 MIR34B MIRLET7C MYC
13 nasopharyngeal carcinoma 29.3 MIR34B MYC NEAT1 PVT1
14 leukemia, chronic lymphocytic 2 29.3 MIR143 MIR145 MIR155 NEAT1 TP53COR1
15 hepatocellular carcinoma 28.8 BAX MIR127 MIR143 MIR145 MIR155 MIRLET7C
16 small non-cleaved cell lymphoma 12.7
17 bare lymphocyte syndrome, type ii 12.0
18 bare lymphocyte syndrome, type i 11.9
19 leukemia, acute lymphoblastic 3 11.3
20 childhood ovarian cancer 11.3
21 blind loop syndrome 11.2
22 hypothyroidism, thyroidal or athyroidal, with spiky hair and cleft palate 11.0
23 blepharitis 11.0
24 leukemia 10.5
25 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 10.4 BCL6 CXCR5
26 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.4 BCL6 MYC
27 neurosyphilis 10.4 CXCL13 CXCR5
28 leukocyte disease 10.3 BAX BCL6 MYC
29 lymphoma, mucosa-associated lymphoid type 10.3 BCL6 CXCL13 CXCR5
30 primary mediastinal large b-cell lymphoma 10.3 BCL6 MYC
31 lymphatic system cancer 10.3 BCL6 MYC SH2D1A
32 lymphocytic leukemia 10.3
33 diversion colitis 10.3 CXCL13 CXCR5
34 mature b-cell neoplasm 10.3 BCL6 MYC PVT1 SH2D1A
35 malaria 10.3
36 hematologic cancer 10.3 BAX BCL6 MYC PVT1
37 intraocular lymphoma 10.3 BCL6 CXCR5
38 polymyositis 10.3 MIR127 MIR155
39 peripheral t-cell lymphoma 10.3 BCL6 CXCL13 MS4A1
40 leukemia, acute lymphoblastic 10.3
41 ovarian serous carcinoma 10.3 MIR143 MIR145
42 b cell prolymphocytic leukemia 10.2 MS4A1 MYC
43 intussusception 10.2
44 pancreatic ductal adenocarcinoma 10.2 MIR143 MIR145 MIR155 PVT1
45 mantle cell lymphoma 10.2 BCL6 MYC SOX11
46 autoimmune lymphoproliferative syndrome, type v 10.2 BCL6 SH2D1A
47 acute pancreatitis 10.2
48 pancreatitis 10.2
49 bladder cancer 10.1 MIR127 MIR143 MIR145 MYC PVT1
50 primary effusion lymphoma 10.1 BCL6 MYC

Graphical network of the top 20 diseases related to Burkitt Lymphoma:



Diseases related to Burkitt Lymphoma

Symptoms & Phenotypes for Burkitt Lymphoma

Symptoms via clinical synopsis from OMIM:

57
Neoplasia:
burkitt lymphoma (b-cell lymphoma)
jaw and kidney tumor (endemic form)
ileal, cecal, ovarian, and breast tumors, occasionally (endemic form)
abdominal tumors (immunodeficiency-associated form)
monomorphic cells, medium-sized, with round nuclei, multiple nucleoli, and moderate amount of cytoplasm
more
Laboratory Abnormalities:
elevated lactate dehydrogenase
elevated uric acid
chromosomal translocations involving c-myc ( , 8q24) and the immunoglobin lambda light chain ( , 22q11.2) locus
chromosomal translocations involving c-myc ( , 8q24) and the immunoglobin kappa light chain ( , 2p12) locus
chromosomal translocations involving c-myc ( , 8q24) and the immunoglobin heavy chain ( , 14q32) locus


Clinical features from OMIM:

113970

Human phenotypes related to Burkitt Lymphoma:

59 32 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 59 32 occasional (7.5%) Occasional (29-5%) HP:0002017
2 hyperuricemia 59 32 frequent (33%) Frequent (79-30%) HP:0002149
3 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
4 abnormality of the ovary 59 32 occasional (7.5%) Occasional (29-5%) HP:0000137
5 intestinal obstruction 59 32 occasional (7.5%) Occasional (29-5%) HP:0005214
6 abnormality of the pancreas 59 32 occasional (7.5%) Occasional (29-5%) HP:0001732
7 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
8 abnormality of the spleen 59 32 occasional (7.5%) Occasional (29-5%) HP:0001743
9 increased lactate dehydrogenase activity 59 32 frequent (33%) Frequent (79-30%) HP:0025435
10 abnormality of the liver 59 32 occasional (7.5%) Occasional (29-5%) HP:0001392
11 abnormality of bone marrow cell morphology 59 32 frequent (33%) Frequent (79-30%) HP:0005561
12 abnormality of the lymph nodes 59 32 occasional (7.5%) Occasional (29-5%) HP:0002733
13 neoplasm of the oral cavity 59 32 frequent (33%) Frequent (79-30%) HP:0100649
14 immunodeficiency 32 HP:0002721
15 decreased number of cd4+ t cells 59 Occasional (29-5%)
16 burkitt lymphoma 32 HP:0030080
17 decreased proportion of cd4-positive t cells 32 occasional (7.5%) HP:0005407

Drugs & Therapeutics for Burkitt Lymphoma

FDA approved drugs:

(show top 50) (show all 227)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Abstral 18 FENTANYL (citrate) ProStrakan January 2011
3
Actiq 18 FENTANYL (citrate) Anesta Corporation November 1998
4
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
5
Afinitor 18 49 EVEROLIMUS Novartis March 2009
6
Akynzeo 18 49 NETUPITANT AND PALONOSETRON (hydrochloride) Helsinn October 2014
7
Alimta 18 49 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
8
Aloxi 18 49 PALONOSETRON (hydrochloride) MGI Pharma, Helsinn Healthcare August 2003
9
Anzemet 18 DOLASETRON MESYLATE Hoechst Marion Roussel February 1998
10
Aredia 18 49 PAMIDRONATE DISODIUM Chiron August 1996
11
Aromasin Tablets 18 49 EXEMESTANE Pharmacia & Upjohn October 21. 1999
12
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
13
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
14
Avastin 18 49 BEVACIZUMAB Genentech July 2009
15
Beleodaq 18 49 BELINOSTAT Spectrum Pharmaceuticals July 2014
16
Bexxar 18 49 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
17
Blincyto 18 49 BLINATUMOMAB Amgen December 2014
18
Bosulif 18 49 BOSUTINIB MONOHYDRATE Pfizer September 2012
19
Bromfenac 18 BROMFENAC SODIUM Duract, Wyeth-Ayerst Laboratories July 1997
20
Busulfex 18 49 BUSULFAN Orphan Medical February 1999
21
Campath 18 49 ALEMTUZUMAB Berlex Laboratories May 2001
22
Cervarix 18 49 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
23
Clolar 18 49 CLOFARABINE Genzyme December, 2004
24
Cometriq 18 49 CABOZANTINIB S-MALATE Exelixis November 2012
25
Cyramza 18 49 RAMUCIRUMAB Eli Lilly April 2014
26
Degarelix 18 49 degarelix Ferring Pharmaceuticals December of 2008
27
Doxil 18 49 DOXORUBICIN HYDROCHLORIDE Alza June 1999
28
Elitek 18 49 RASBURICASE sanofi-aventis October 2009
29
Ellence 18 49 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
30
Elliotts B Solution 18 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
31
Eloxatin 18 49 OXALIPLATIN Sanofi-aventis August 2002
32
Emend 18 49 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003
33
Erbitux 18 49 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
34
Erivedge 18 49 VISMODEGIB Genentech January 2012
35
Erwinaze 18 49 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
36
Ethyol 18 AMIFOSTINE Alza December 8, 1995
37
Eulexin 18 FLUTAMIDE Schering-Plough June 1996
38
Evista 18 49 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
39
Farydak 18 49 PANOBINOSTAT LACTATE Novartis February 2015
40
Faslodex 18 49 FULVESTRANT AstraZeneca April 2002
41
Femara 18 49 LETROZOLE Novartis January 2001
42
Feridex I.V. 18 FERUMOXIDES Advanced Magnetics February 1996
43
Folotyn 18 49 PRALATREXATE Allos Therapeutics September 2009
44
Fusilev 18 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
45
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
46
Gazyva 18 49 OBINUTUZUMAB Genentech October of 2013
47
Gemzar 18 49 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
48
Gilotrif 18 49 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
49
Gleevec 18 49 IMATINIB MESYLATE Novartis May 2001
50
Gliadel Wafer 18 49 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997

Drugs for Burkitt Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 503)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-22-7, 2068-78-2 5978
2
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
5
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 147-94-4 6253
6
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 174722-31-7 10201696
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 1177-87-3
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-02-2 5743
9
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
10
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-24-8 5755
11
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302-25-0
12
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2921-57-5
13
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83-43-2 6741
14
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
15
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 23214-92-8 31703
16
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
17
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
18
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
19
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-05-9 6006 143
20
Teniposide Approved Phase 4,Phase 2,Phase 1 29767-20-2 34698
21
Thioguanine Approved Phase 4,Phase 3,Phase 2 154-42-7 2723601
22
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
23
Cetylpyridinium Approved Phase 4 7773-52-6
24
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
26
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
27
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 31703
28
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2920-86-7
29
Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1 0
30 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
34 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Not Applicable
39 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
44 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
45 Prednisolone acetate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
47 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
49 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
50 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 747)
# Name Status NCT ID Phase Drugs
1 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
2 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Unknown status NCT02585947 Phase 4 Tenofovir
3 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
4 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
5 A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients Not yet recruiting NCT03677596 Phase 4 inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
6 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
7 Cetylpyridium Chloride (CPC) Based Chewing Gum and Gingivitis Active, not recruiting NCT03219840 Phase 4 CPC;Placebo
8 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
9 LMBA02 Protocol for Patients With a Burkitt Lymphoma Unknown status NCT00180882 Phase 3 rituximab
10 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
11 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
12 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
13 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
14 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
15 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
16 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
17 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
18 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
19 Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia Recruiting NCT02101853 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Dexamethasone;Etoposide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Mitoxantrone Hydrochloride;Pegaspargase;Therapeutic Hydrocortisone;Thioguanine;Vincristine Sulfate
20 CART-19 Cells For R/R B-ALL Recruiting NCT03391739 Phase 2, Phase 3
21 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Recruiting NCT02883049 Phase 3 Clofarabine;Cyclophosphamide;Cytarabine;Dasatinib;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
22 Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Completed NCT00381680 Phase 3 vincristine sulfate;prednisone;doxorubicin hydrochloride;pegaspargase;cytarabine;methotrexate;dexamethasone;etoposide;cyclophosphamide;leucovorin calcium;asparaginase;mercaptopurine
23 Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
24 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Recruiting NCT03117751 Phase 2, Phase 3 Prednisone;Vincristine;Daunorubicin;Pegaspargase;Erwinase®;Rituximab;Cyclophosphamide;Cytarabine;Mercaptopurine;Dasatinib;Methotrexate;Blinatumomab;Ruxolitinib;Bortezomib;Dexamethasone;Doxorubicin;Etoposide;Clofarabine;Vorinostat;Idarubicin;Nelarabine
25 Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL) Terminated NCT00500240 Phase 3 Insulin Glargine;Insulin Aspart
26 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Active, not recruiting NCT01190930 Phase 3 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
27 Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas Completed NCT00554164 Phase 3 (R-)CHOP protocol;B-ALL protocol;(R-)CHOP protocol;(R-)CHOP protocol
28 S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Terminated NCT00006708 Phase 3 carboplatin;etoposide;ifosfamide
29 Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
30 Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Suspended NCT02443077 Phase 3 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Ibrutinib;Melphalan
31 Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis Completed NCT00838214 Phase 2, Phase 3 budesonide;prednisone
32 Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL Recruiting NCT01228331 Phase 2, Phase 3 Amsacrine;Clofarabine;Cyclophosphamide;Cytarabine;Daunorubicin hydrochloride;Dexamethasone;Doxorubicin hydrochloride;Etoposide phosphate;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Thioguanine;Vincristine sulfate
33 International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia Active, not recruiting NCT01117441 Phase 3 PEG-L-asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine;daunoxome;fludarabine
34 Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia Completed NCT00005977 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;vincristine sulfate
35 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
36 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Active, not recruiting NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
37 Double Cord Versus Haploidentical (BMT CTN 1101) Active, not recruiting NCT01597778 Phase 3
38 Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
39 Mature B-Cell Lymphoma And Leukemia Study III Recruiting NCT01046825 Phase 2, Phase 3 COPAD;COP, COPD M3, CYM;COP, COPADM8, CYVE
40 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma Completed NCT00003595 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
41 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
42 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
43 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
44 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
45 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
46 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
47 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
48 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
49 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
50 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B

Search NIH Clinical Center for Burkitt Lymphoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Burkitt Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: burkitt lymphoma

Genetic Tests for Burkitt Lymphoma

Genetic tests related to Burkitt Lymphoma:

# Genetic test Affiliating Genes
1 Burkitt Lymphoma 29 MYC

Anatomical Context for Burkitt Lymphoma

MalaCards organs/tissues related to Burkitt Lymphoma:

41
B Cells, Bone, Lung, Bone Marrow, T Cells, Endothelial, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Burkitt Lymphoma:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Burkitt Lymphoma

Articles related to Burkitt Lymphoma:

(show top 50) (show all 1402)
# Title Authors Year
1
Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. ( 30276438 )
2019
2
Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. ( 30546948 )
2019
3
Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. ( 29774105 )
2018
4
Primary jejunal Burkitt lymphoma in a child: ultrasonic detection. ( 29770187 )
2018
5
In vitro evaluation of the enantiomeric R- and S-1,1'-binaphthyl-2,2'-diaminodichlorido-Pt(ii) complexes in human Burkitt lymphoma cells: emphasis on cellular accumulation, cytotoxicity, DNA binding, and ability to induce apoptosis. ( 29333543 )
2018
6
Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. ( 29209924 )
2018
7
Widely disseminated sporadic Burkitt lymphoma initially presented as oral manifestations in a 6-year-old boy. ( 29892537 )
2018
8
Adult multicentric burkitt lymphoma with bowel obstruction due to intussusception. ( 29755022 )
2018
9
Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin. ( 28583033 )
2018
10
MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells. ( 29318382 )
2018
11
Frequency of EBV LMP-1 Promoter and Coding Variations in Burkitt Lymphoma Samples in Africa and South America and Peripheral Blood in Uganda. ( 29865259 )
2018
12
Molecular and Cytogenetic Studies in a Child with Burkitt Lymphoma and Ataxia-Telangiectasia Syndrome Harboring MYC Overexpression and Partial Trisomy 8. ( 29071822 )
2018
13
A comparative study of RNA-Seq and microarray data analysis on the two examples of rectal-cancer patients and Burkitt Lymphoma cells. ( 29768462 )
2018
14
Primary Hepatic Burkitt Lymphoma in a Kidney Transplant Recipient. ( 29862100 )
2018
15
A Case of Jejunal Intussusception caused by Burkitt Lymphoma in an Acquired Immunodeficiency Syndrome Patient. ( 29637755 )
2018
16
Upregulation of the Chemokine Receptor CCR2B in Epsteina89Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program. ( 29751565 )
2018
17
Plasma magnesium is inversely associated with Epstein-Barr virus load in peripheral blood and Burkitt lymphoma in Uganda. ( 29248801 )
2018
18
CAR T cells induce a complete response in refractory Burkitt Lymphoma. ( 29795432 )
2018
19
Low expression of Mda-7/IL-24 and high expression of C-myb in tumour tissues are predictors of poor prognosis for Burkitt lymphoma patients. ( 29415639 )
2018
20
'Blastoid' variant of Burkitt lymphoma with additional partial 1q tetrasomy. ( 29725528 )
2018
21
Primary gastric Burkitt lymphoma-induced anaemia: a case report and a literature review. ( 29928154 )
2018
22
The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. ( 29295643 )
2018
23
Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. ( 29741758 )
2018
24
Hepatobiliary and Pancreatic: Burkitt lymphoma mimicking IgG4-related disease. ( 29808497 )
2018
25
False-Positive 18F-FDG PET/CT Due to Filgrastim That Induced Extramedullary Liver Hematopoiesis in a Burkitt Lymphoma. ( 29401143 )
2018
26
The changing clinical pattern of endemic Burkitt lymphoma in Western Africa: Experience from a tertiary center in Ghana. ( 29873879 )
2018
27
Risk factors for Burkitt lymphoma: a nested case-control study in the UK Clinical Practice Research Datalink. ( 29676453 )
2018
28
How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa. ( 29769263 )
2018
29
Metachronous renal Ewing sarcoma/primitive neuroectodermal tumour in a survivor of Burkitt lymphoma. ( 29895547 )
2018
30
Primary bilateral ovarian Burkitt lymphoma; a rare issue in gynecologic oncology. ( 29876052 )
2018
31
Sporadic Burkitt Lymphoma Mimicking an Adnexal Tumor. ( 29908337 )
2018
32
Burkitt lymphoma diagnosed on 11C-Methionine cerebral PET in an HIV-positive patient with undetermined brain injury. ( 30061068 )
2018
33
Coordinated repression of BIM and PUMA by Epstein-Barr virus latent genes maintains the survival of Burkitt lymphoma cells. ( 28960205 )
2018
34
TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line. ( 29048125 )
2018
35
Argonaute 2 RNA Immunoprecipitation Reveals Distinct miRNA Targetomes of Primary Burkitt Lymphoma Tumors and Normal B Cells. ( 29458013 )
2018
36
Low rate of spleen involvement in sporadic Burkitt lymphoma at staging on PET-CT. ( 29460043 )
2018
37
Burkitt Lymphoma of the Temporal Bone. ( 29595582 )
2018
38
Duodenocolonic Fistula As A Rare Complication of Intestinal Burkitt Lymphoma in a Three-Year-Old Boy. ( 29618138 )
2018
39
Ethmoidal and extranodal Burkitt lymphoma in a child with bilateral kidney Burkitt lymphoma lesions incidentally detected by 18F-FDG PET/CT. ( 29636232 )
2018
40
Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells. ( 29669863 )
2018
41
Erratum to "Plasma magnesium is inversely associated with Epstein-Barr virus load in peripheral blood and Burkitt lymphoma in Uganda" [Cancer Epidemiol. 52 (2018) 70-74]. ( 29861403 )
2018
42
Infection of Epstein⁻Barr Virus in Type III Latency Modulates Biogenesis of Exosomes and the Expression Profile of Exosomal miRNAs in the Burkitt Lymphoma Mutu Cell Lines. ( 30029522 )
2018
43
Primary CNS Burkitt Lymphoma: A Case Report of a 55-Year-Old Cerebral Palsy Patient. ( 30034894 )
2018
44
Burkitt lymphoma of the thyroid gland. ( 30036431 )
2018
45
Burkitt lymphoma of the stomach in an immunocompetent patient. ( 30036508 )
2018
46
FAB LMB 96 Regimen for Newly Diagnosed Burkitt Lymphoma in Children: Single-center Experience. ( 30059355 )
2018
47
Successful Use of EPOCH-R in 2 Young Adult Patients With Burkitt Lymphoma and Acute Kidney Injury: A Case Report. ( 30095692 )
2018
48
Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma. ( 30104685 )
2018
49
miR-129 targets CDK1 and iASPP to modulate Burkitt lymphoma cell proliferation in a TAp63-dependent manner. ( 30105797 )
2018
50
MicroRNA-4728 serves as a suppressor and antagonist of oncogenic MAPK in Burkitt lymphoma. ( 30108451 )
2018

Variations for Burkitt Lymphoma

ClinVar genetic disease variations for Burkitt Lymphoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MYC NM_002467.5(MYC): c.214C> T (p.Pro72Ser) single nucleotide variant Pathogenic rs28933407 GRCh37 Chromosome 8, 128750677: 128750677
2 MYC NM_002467.5(MYC): c.214C> T (p.Pro72Ser) single nucleotide variant Pathogenic rs28933407 GRCh38 Chromosome 8, 127738431: 127738431
3 MYC NM_002467.5(MYC): c.302A> C (p.Asn101Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121918683 GRCh37 Chromosome 8, 128750765: 128750765
4 MYC NM_002467.5(MYC): c.302A> C (p.Asn101Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121918683 GRCh38 Chromosome 8, 127738519: 127738519
5 MYC NM_002467.5(MYC): c.162G> C (p.Glu54Asp) single nucleotide variant Pathogenic rs121918684 GRCh37 Chromosome 8, 128750625: 128750625
6 MYC NM_002467.5(MYC): c.162G> C (p.Glu54Asp) single nucleotide variant Pathogenic rs121918684 GRCh38 Chromosome 8, 127738379: 127738379
7 MYC NM_002467.5(MYC): c.220C> G (p.Pro74Ala) single nucleotide variant Pathogenic rs121918685 GRCh37 Chromosome 8, 128750683: 128750683
8 MYC NM_002467.5(MYC): c.220C> G (p.Pro74Ala) single nucleotide variant Pathogenic rs121918685 GRCh38 Chromosome 8, 127738437: 127738437

Cosmic variations for Burkitt Lymphoma:

9 (show top 50) (show all 76)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10725 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.701A>G p.Y234C 17:7674262-7674262 9
2 COSM45844 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.274C>G p.P92A 17:7676095-7676095 9
3 COSM10777 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.715A>G p.N239D 17:7674248-7674248 9
4 COSM43689 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.482C>T p.A161V 17:7675130-7675130 9
5 COSM43965 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.734G>C p.G245A 17:7674229-7674229 9
6 COSM10656 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.742C>T p.R248W 17:7674221-7674221 9
7 COSM43565 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.857A>G p.E286G 17:7673763-7673763 9
8 COSM44103 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.737T>A p.M246K 17:7674226-7674226 9
9 COSM36146 SOCS1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.391C>A p.Q131K 16:11255088-11255088 9
10 COSM5227 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.182A>T p.H61L 10:87925530-87925530 9
11 COSM5151 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.1003C>T p.R335* 10:87961095-87961095 9
12 COSM5203 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.496G>C p.V166L 10:87952121-87952121 9
13 COSM37032 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.1937A>G p.Y646C 7:148811635-148811635 9
14 COSM12513 CDKN2A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.298G>T p.A100S 9:21971061-21971061 9
15 COSM21826 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.2572T>C p.F858L 11:108267276-108267276 9
16 COSM21827 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.3161C>G p.P1054R 11:108272729-108272729 9
17 COSM21825 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.1229T>C p.V410A 11:108249096-108249096 9
18 COSM5702591 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
19 COSM28746 IDH1 central nervous system,brain,other,neoplasm c.395G>A p.R132H 2:208248388-208248388 3
20 COSM28750 IDH1 central nervous system,brain,other,neoplasm c.395G>T p.R132L 2:208248388-208248388 3
21 COSM28749 IDH1 central nervous system,brain,other,neoplasm c.394C>G p.R132G 2:208248389-208248389 3
22 COSM28748 IDH1 central nervous system,brain,other,neoplasm c.394C>A p.R132S 2:208248389-208248389 3
23 COSM28747 IDH1 central nervous system,brain,other,neoplasm c.394C>T p.R132C 2:208248389-208248389 3
24 COSM5702574 FOXO3 central nervous system,brain,other,neoplasm c.583A>T p.K195* 6:108561791-108561791 3
25 COSM5702592 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
26 COSM6986772 TRAF2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.152A>G p.H51R 9:136898892-136898892 1
27 COSM44910 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.403T>A p.C135S 17:7675209-7675209 1
28 COSM10648 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.524G>A p.R175H 17:7675088-7675088 1
29 COSM10995 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.580C>T p.L194F 17:7674951-7674951 1
30 COSM4721653 RICTOR haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3712C>T p.R1238* 5:38950136-38950136 1
31 COSM190567 RHOA haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.206T>C p.L69P 3:49368499-49368499 1
32 COSM5274 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.484G>C p.D162H 10:87933243-87933243 1
33 COSM5036 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.202T>C p.Y68H 10:87925550-87925550 1
34 COSM6987562 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.331T>G p.W111G 10:87933090-87933090 1
35 COSM30627 PIK3CA haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3109G>A p.E1037K 3:179234266-179234266 1
36 COSM85940 MYD88 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.794T>C p.L265P 3:38141150-38141150 1
37 COSM6987557 MSH6 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.493T>C p.F165L 2:47795929-47795929 1
38 COSM2006760 KMT2D haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.12952C>T p.Q4318* 12:49030678-49030678 1
39 COSM6987497 KDM6A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3406A>G p.M1136V 23:45083581-45083581 1
40 COSM6949886 HGF haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.986G>T p.W329L 7:81729659-81729659 1
41 COSM6948355 GRIN2A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2453C>T p.A818V 16:9768993-9768993 1
42 COSM37029 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1937A>C p.Y646S 7:148811635-148811635 1
43 COSM37031 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1936T>A p.Y646N 7:148811636-148811636 1
44 COSM52944 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2645G>A p.R882H 2:25234373-25234373 1
45 COSM6987563 DIS3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2597A>C p.K866T 13:72761436-72761436 1
46 COSM6987564 CTCF haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1282C>G p.Q428E 16:67621516-67621516 1
47 COSM12475 CDKN2A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.238C>T p.R80* 9:21971121-21971121 1
48 COSM21828 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2932T>C p.S978P 11:108271261-108271261 1
49 COSM22488 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.8494C>T p.R2832C 11:108345818-108345818 1
50 COSM21829 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.8138G>A p.R2713K 11:108335096-108335096 1

Copy number variations for Burkitt Lymphoma from CNVD:

7 (show top 50) (show all 157)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13309 1 150547027 150552214 Copy number MCL1 Burkitt''s lymphoma
2 17456 1 142870000 177000000 Gain BCA2 Burkitt''s lymphoma
3 17457 1 142870000 177000000 Gain BCL9 Burkitt''s lymphoma
4 17458 1 142870000 177000000 Gain LHX4 Burkitt''s lymphoma
5 17459 1 142870000 177000000 Gain PIAS3 Burkitt''s lymphoma
6 20085 1 15300000 212100000 Insertion NOTCH2 Burkitt''s lymphoma
7 22188 1 166155454 171863618 Gain FASLG Burkitt''s lymphoma
8 25990 1 195253751 195672280 Gain PTPRC Burkitt''s lymphoma
9 26526 1 200970000 201360000 Gain LRRN5 Burkitt''s lymphoma
10 26527 1 200970000 201360000 Gain MDM4 Burkitt''s lymphoma
11 26528 1 200970000 201360000 Gain PIK3C2B Burkitt''s lymphoma
12 26529 1 200970000 201360000 Gain PLEKHA6 Burkitt''s lymphoma
13 26530 1 200970000 201360000 Gain PPP1R15B Burkitt''s lymphoma
14 29698 1 23457835 23714048 Loss E2F2 Burkitt''s lymphoma
15 30116 1 240240000 241350000 Gain ADSS Burkitt''s lymphoma
16 30117 1 240240000 241350000 Gain AKT3 Burkitt''s lymphoma
17 30118 1 240240000 241350000 Gain C1orf100 Burkitt''s lymphoma
18 30119 1 240240000 241350000 Gain C1orf101 Burkitt''s lymphoma
19 30120 1 240240000 241350000 Gain C1orf121 Burkitt''s lymphoma
20 30121 1 240240000 241350000 Gain FAM36A Burkitt''s lymphoma
21 30122 1 240240000 241350000 Gain HNRPU Burkitt''s lymphoma
22 30123 1 240240000 241350000 Gain LOC440742 Burkitt''s lymphoma
23 30124 1 240240000 241350000 Gain ZNF238 Burkitt''s lymphoma
24 42609 10 36983732 37133784 Loss Burkitt''s lymphoma
25 48364 11 1 32410000 Loss FANCF Burkitt''s lymphoma
26 48365 11 1 32410000 Loss PLEKHA7 Burkitt''s lymphoma
27 49723 11 110620000 110810000 Gain C11orf53 Burkitt''s lymphoma
28 49724 11 110620000 110810000 Gain POU2AF1 Burkitt''s lymphoma
29 50222 11 115828212 118580638 Gain Burkitt''s lymphoma
30 50968 11 120700000 134452384 Deletion Burkitt''s lymphoma
31 51055 11 122263650 134452384 Loss Burkitt''s lymphoma
32 51545 11 127825348 127931093 Gain ETS1 Burkitt''s lymphoma
33 64462 12 128465362 132449811 Gain Burkitt''s lymphoma
34 67044 12 35400000 132349534 Insertion Burkitt''s lymphoma
35 70408 12 61724591 82263925 Gain Burkitt''s lymphoma
36 74099 13 100500000 109100000 Insertion Burkitt''s lymphoma
37 74289 13 103640000 112610000 Loss ANKRD10 Burkitt''s lymphoma
38 74290 13 103640000 112610000 Loss ARHGEF7 Burkitt''s lymphoma
39 74291 13 103640000 112610000 Loss COL4A1 Burkitt''s lymphoma
40 74292 13 103640000 112610000 Loss COL4A2 Burkitt''s lymphoma
41 74293 13 103640000 112610000 Loss EFNB2 Burkitt''s lymphoma
42 74294 13 103640000 112610000 Loss ERCC5 Burkitt''s lymphoma
43 74295 13 103640000 112610000 Loss FGF14 Burkitt''s lymphoma
44 74296 13 103640000 112610000 Loss ING1 Burkitt''s lymphoma
45 74297 13 103640000 112610000 Loss IRS2 Burkitt''s lymphoma
46 74298 13 103640000 112610000 Loss LIG4 Burkitt''s lymphoma
47 74299 13 103640000 112610000 Loss PCCA Burkitt''s lymphoma
48 74300 13 103640000 112610000 Loss RAB20 Burkitt''s lymphoma
49 74301 13 103640000 112610000 Loss SLC10A2 Burkitt''s lymphoma
50 74302 13 103640000 112610000 Loss TNFSF13B Burkitt''s lymphoma

Expression for Burkitt Lymphoma

Search GEO for disease gene expression data for Burkitt Lymphoma.

Pathways for Burkitt Lymphoma

Pathways related to Burkitt Lymphoma according to KEGG:

37
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203
2 Epstein-Barr virus infection hsa05169

GO Terms for Burkitt Lymphoma

Cellular components related to Burkitt Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.17 MIR127 MIR143 MIR145 MIR155 MIR34B MIRLET7C

Biological processes related to Burkitt Lymphoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 leukocyte chemotaxis GO:0030595 9.51 CXCL13 CXCR5
2 regulation of smooth muscle contraction GO:0006940 9.49 MIR143 MIR145
3 negative regulation of glucose import GO:0046325 9.48 MIR143 MYC
4 positive regulation of connective tissue replacement GO:1905205 9.46 MIR155 MIR34B
5 hypothalamus development GO:0021854 9.43 BAX MYC
6 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.4 MIR155 MIR34B
7 angiotensin-activated signaling pathway GO:0038166 9.37 MIR143 MIR145
8 germinal center formation GO:0002467 9.32 BCL6 CXCL13
9 aorta smooth muscle tissue morphogenesis GO:0060414 9.26 MIR143 MIR145
10 gene silencing by miRNA GO:0035195 9.17 MIR127 MIR143 MIR145 MIR155 MIR34B MIRLET7C
11 regulation of phenotypic switching GO:1900239 9.16 MIR143 MIR145
12 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 8.96 MIR143 MIR145

Molecular functions related to Burkitt Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR143 MIR145 MIR155 MIRLET7C